Skip to main content
Treatment of MRI-Diagnosed Trigeminal Peripheral Nerve Sheath Tumors by Stereotactic Radiotherapy in Dogs.
- Author(s): Hansen, KS;
- Zwingenberger, AL;
- Théon, AP;
- Pfeiffer, I;
- Kent, MS
- et al.
Published Web Locationhttps://doi.org/10.1111/jvim.13970
BackgroundStereotactic radiotherapy (SRT) is an emerging technique for treating tumors in animals.
ObjectivesTo assess the outcome of dogs with suspected intracranial trigeminal nerve peripheral nerve sheath tumors (PNST) treated with SRT.
AnimalsEight dogs with presumptive PNST.
MethodsThis was a retrospective study of dogs identified by searching UC Davis Veterinary Medical Teaching Hospital medical records for dogs treated with SRT for a presumed PNST. Presumptive diagnosis was based on magnetic resonance imaging. SRT was delivered in 3 dose fractions of 8 Gray (Gy) on consecutive days or every other day to a total dose of 24 Gy.
ResultsMedian disease-specific survival was 745 days (range: 99-1375 days, n = 6). No signs of acute adverse effects of radiation treatment were recorded. Late radiation effects versus tumor progression could not be confirmed histopathologically because of few animals undergoing necropsy.
Conclusions and clinical importanceThis study provides preliminary evidence that dogs with PNST benefit from SRT in terms of long-term survival. The treatment appears to be well tolerated and requires fewer anesthetic events for animals compared to full-course radiation.
For improved accessibility of PDF content, download the file to your device.